OR WAIT null SECS
The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.
On April 19, 2023, a leaked abstract from the European Hematology Association concerning a joint Phase III study from Johnson & Johnson and Legend Biotech. The Phase III trial (CARITUDE-4) showed that patients with multiple myeloma treated with Carvykti (ciltacabtagene autoleucel), a chimeric antigen receptor T cell (CAR-T) therapy, had a 74% drop in risk of disease progression relative to standard treatment. The leak has since been taken down.
On April 20, Legend Biotech announced that it had raised $200 million from private investors buying stock. A Yahoo finance report found that the company’s stock jumped approximately 20% following the leak; the same report indicated that the company’s stocks have risen 59.9% over the past year, significantly outpacing the industry’s overall 10.2% decline.
In the days following the leak, company representatives have refused to confirm the data until it is officially made public. The data are scheduled to be made public in meetings with the European Hematology Association and American Society of Clinical Oncology on May 11, 2023, and May 25, 2023, respectively.
Source: Legend Biotech, Yahoo Finance
Editors Note: An earlier version of this article did not make explicit mention of the leak stemming from EHA.